Sobi – Swedish Orphan Biovitrum

In Sobi we have made research into rare diseases our mission. We call ourselves pioneers, and every day we refuse to accept the status quo. Because witnessing the challenges facing so many people with rare diseases has taught us to find new ways to help them and make their lives better.


Every year we invest 12% of our turnover in research and development to bring innovative therapies to the areas in which we are primarily engaged: haematology, immunology and specialty care. We were among the first to clone DNA to produce recombinant treatment for haemophilia and have made available therapies for people with previously hopeless diseases, such as hereditary type 1 tyrosinemia.


We bring something rare to rare diseases: the strength of our focus and agility and new life chances for the people to whom we dedicate the work of our 1050 employees worldwide. A force that we are proud to call “rare”, encapsulating it in our logo: “Sobi rare strength”.


Our headquarter is in Stockholm, but we are present in 25 countries in Europe, North America, the Middle East, Russia and North Africa, and we distribute drugs in more than 60 countries worldwide. Sobi is listed on Nasdaq in Stockholm (STO:SOBI) and in 2018 our turnover was SEK 9.1 billion. We have been present in Italy since 2008. For more information:




Viale Lancetti, 43 – 20158 Milano